Looking beyond the numbers: Interpreting patient experience of rozanolixizumab in generalized myasthenia gravis from the MycarinG clinical trial

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

MG Symptoms PRO scores were developed by UCB¹ and have not been validated in any languages for use in MG. The MG Symptoms PRO analysis was part of the planned efficacy analysis; however, efficacy or clinical significance should be interpreted with caution.

1. Cleanthous S, et al. Orphanet J Rare Dis. 2021;16:457.